A new paediatric formulation of roxithromycin was tested for acceptability, efficacy and safety in a multicentre, prospective, non-comparative trial in 210 children, aged between 2 and 8 years, with a variety of respiratory tract infections. Most children were diagnosed as having rhinobronchitis, acute pharyngitis or acute tonsillitis. A dose of 5-8 mg/kg/day (mean +/- SD, 5.92 +/- 1.12) roxithromycin was given orally for 5-10 days (mean +/- SDL 6.86 +/- 1.80). The formulation consists of a tablet for suspension in a small volume of water, administered using a spoon, twice daily. Acceptability was good, with only eight children refusing their medication because of the taste or because of vomiting. The method of administration was found to be convenient by 76% of parents. The clinical success rate was 89.1% in the intent-to-treat analysis. There were only 18 adverse events reported by 14 patients; of these, only 10 events (all gastrointestinal) in eight patients were classified as drug related. A total of eight patients discontinued treatment because of an adverse event, but in only four were the events drug related.
In a multicenter, randomized, doubleblind parallel trial, the efficacy and safety of loratadine and cetirizine were compared in 118 adults with atopic dermatitis. Symptomatic improvements and efficacy, as rated by physicians and patients, were generally similar for the two treatments. Both drugs were well tolerated; 25% of the patients who received lorata-dine and 27% of those treated with cetirizine reported at least one adverse event. However, the incidence of somnolence was 9% with cetirizine and only 3% with loratadine. In the management of symptoms of atopic dermatitis, loratadine is as effective as cetirizine and is less sedating. (I Dermatol Treat (1997) 8: 249 -253)
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations鈥揷itations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.